Table 1.
FoxO role in cell sensitivity and resistance to conventional agents.
| Tumor | Drug | Mechanism of Response | Ref | |
|---|---|---|---|---|
| Ovarian carcinoma | paclitaxel | Increased levels and transcriptional activity of FoxO1. | Resistance | [62] |
| Ovarian carcinoma | cisplatin combined with selinexor | Enrichment of FoxO1 nuclear localization. | Sensitivity | [63] |
| Ovarian carcinoma | cisplatin | Down-regulation of FoxO1 levels. | Resistance | [64] |
| Colon carcinoma | cisplatin | FoxO3 dephosphorylation (threonine 32) and nuclear translocation. | Sensitivity | [65] |
| Colangiocarcinoma | cisplatin | Increased transcriptional activity of FoxO3 (up-regulation of Keap1) and activation of proteasome pathway. | Sensitivity | [66] |
| Esophageal squamous cell carcinoma | cisplatin, paclitaxel | FoxO1 stimulation of TGF-β1 expression. | Resistance | [67] |
| Hepatocellular carcinoma | cisplatin, doxorubicin | Suppression of FoxO1 activity (down-regulation of the pro-apoptotic Bim). | Resistance | [68] |
| Breast cancer | doxorubicin | FoxO1 reduced levels and nuclear localization. | Resistance | [69] |
| Breast cancer | doxorubicin | FoxO1 over-expression (up-regulation of ABCB1). | Resistance | [70] |
| Leukemic cells | doxorubicin | FoxO3 activation (stimulation of ABCB1 expression). | Resistance | [71] |
| Neuroblastoma | doxorubicin and etoposide | FoxO3-mediated reduction of survivin expression. | Sensitivity | [72] |
| Nasopharyngeal carcinoma | 5-fluorouracil | miR-3188-mTOR-p-PI3K/AKT-c-JUN feedback loop modulated by FoxO1 sensitize cells. | Sensitivity | [73] |
| Colon carcinoma | 5-fluorouracil | FoxO3 nuclear translocation (down-regulation BAK, BIM, KIP). | Resistance | [74] |